Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

XOMA

Nasdaq:XOMA
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
XOMA
Nasdaq
$185M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
  • XOMA has significant price volatility in the past 3 months.
XOMA Share Price and Events
7 Day Returns
22.9%
NasdaqGM:XOMA
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
53.5%
NasdaqGM:XOMA
1.6%
US Biotechs
-9.1%
US Market
XOMA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
XOMA (XOMA) 22.9% -20.1% -33% 53.5% 167.2% -73.2%
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • XOMA outperformed the Biotechs industry which returned 1.6% over the past year.
  • XOMA outperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
XOMA
Industry
5yr Volatility vs Market
Related Companies

Value

 Is XOMA undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for XOMA. This is due to cash flow or dividend data being unavailable. The share price is $19.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for XOMA's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are XOMA's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:XOMA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.23
NasdaqGM:XOMA Share Price ** NasdaqGM (2020-03-27) in USD $19
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of XOMA.

NasdaqGM:XOMA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:XOMA Share Price ÷ EPS (both in USD)

= 19 ÷ -0.23

-84x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • XOMA is loss making, we can't compare its value to the US Biotechs industry average.
  • XOMA is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does XOMA's expected growth come at a high price?
Raw Data
NasdaqGM:XOMA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -84x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
61.4%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for XOMA, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on XOMA's assets?
Raw Data
NasdaqGM:XOMA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $4.51
NasdaqGM:XOMA Share Price * NasdaqGM (2020-03-27) in USD $19
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:XOMA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:XOMA Share Price ÷ Book Value per Share (both in USD)

= 19 ÷ 4.51

4.22x

* Primary Listing of XOMA.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • XOMA is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess XOMA's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. XOMA has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is XOMA expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
61.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is XOMA expected to grow at an attractive rate?
  • XOMA's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • XOMA's earnings growth is expected to exceed the United States of America market average.
  • XOMA's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:XOMA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:XOMA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 61.4%
NasdaqGM:XOMA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 19.1%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:XOMA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:XOMA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 39 18 3
2023-12-31 27 7 3
2022-12-31 24 3 3
2021-12-31 16 -4 3
2020-12-31 13 -8 3
2020-03-28
NasdaqGM:XOMA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 18 0 -2
2019-09-30 20 1 -2
2019-06-30 12 -5 -8
2019-03-31 13 -6 -6
2018-12-31 5 -13 -13
2018-09-30 9 -15 -11
2018-06-30 44 18 9
2018-03-31 53 13 18
2017-12-31 53 3 6
2017-09-30 48 15 -11
2017-06-30 12 -28 -39
2017-03-31 2 -32 -61

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • XOMA's earnings are expected to grow significantly at over 20% yearly.
  • XOMA's revenue is expected to grow by 19.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:XOMA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from XOMA Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:XOMA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 1.18 2.26 -0.55 3.00
2023-12-31 0.33 1.52 -0.55 3.00
2022-12-31 0.07 1.19 -0.70 3.00
2021-12-31 -0.47 -0.06 -0.85 3.00
2020-12-31 -0.81 -0.49 -1.10 3.00
2020-03-28
NasdaqGM:XOMA Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.23
2019-09-30 -0.19
2019-06-30 -0.98
2019-03-31 -0.74
2018-12-31 -1.59
2018-09-30 -1.35
2018-06-30 1.15
2018-03-31 2.29
2017-12-31 0.75
2017-09-30 -1.54
2017-06-30 -5.94
2017-03-31 -9.84

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if XOMA will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess XOMA's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
XOMA has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has XOMA performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare XOMA's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • XOMA does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare XOMA's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare XOMA's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
XOMA's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from XOMA Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:XOMA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 18.37 -1.98 20.10
2019-09-30 19.63 -1.65 21.04
2019-06-30 11.67 -8.43 19.87
2019-03-31 12.97 -6.30 19.33
2018-12-31 5.30 -13.34 18.56
2018-09-30 8.97 -11.23 20.95
2018-06-30 44.26 9.39 23.55
2018-03-31 52.89 18.23 24.34
2017-12-31 52.69 5.71 24.34
2017-09-30 47.86 -10.87 22.81 42.83
2017-06-30 12.31 -39.43 19.61 42.83
2017-03-31 1.86 -61.48 19.18 42.83
2016-12-31 5.56 -53.53 18.32 42.83
2016-09-30 53.22 -10.70 18.55 11.44
2016-06-30 54.66 1.35 20.12 23.44
2016-03-31 56.76 -7.25 20.41 37.34
2015-12-31 55.45 -20.61 20.62 50.15
2015-09-30 11.61 -53.28 20.01 52.19
2015-06-30 14.67 -67.19 19.73 52.78
2015-03-31 18.11 -55.33 19.83 49.98
2014-12-31 18.87 -38.30 19.87 51.28
2014-09-30 27.05 -83.28 20.82 86.14
2014-06-30 28.23 -98.51 20.69 53.62
2014-03-31 29.41 -103.86 19.61 62.46
2013-12-31 35.45 -124.06 18.48 47.49
2013-09-30 30.31 -69.39 17.38 6.67
2013-06-30 31.25 -66.62 16.82 35.07
2013-03-31 33.37 -65.53 16.31 23.85

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if XOMA has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if XOMA has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if XOMA improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess XOMA's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
XOMA has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is XOMA's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up XOMA's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • XOMA is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • XOMA's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of XOMA's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from XOMA Company Filings, last reported 2 months ago.

NasdaqGM:XOMA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 43.99 32.28 56.69
2019-09-30 25.79 32.68 39.74
2019-06-30 20.99 26.02 42.33
2019-03-31 24.03 22.58 48.44
2018-12-31 18.79 22.48 45.78
2018-09-30 1.15 22.03 28.43
2018-06-30 4.85 14.85 38.69
2018-03-31 5.64 14.57 41.97
2017-12-31 5.79 14.57 43.47
2017-09-30 4.06 14.32 47.75
2017-06-30 -29.12 27.86 12.47
2017-03-31 -31.21 26.63 20.05
2016-12-31 -47.21 43.17 25.74
2016-09-30 -31.19 45.22 20.62
2016-06-30 -20.45 46.52 34.30
2016-03-31 -7.53 46.25 46.61
2015-12-31 -2.31 48.67 66.26
2015-09-30 -29.19 48.59 32.05
2015-06-30 -31.29 48.00 50.96
2015-03-31 -13.38 47.19 67.49
2014-12-31 3.10 35.31 78.45
2014-09-30 -18.13 36.59 59.06
2014-06-30 -7.57 38.30 75.89
2014-03-31 1.74 38.74 93.70
2013-12-31 -3.99 40.99 121.65
2013-09-30 -13.54 41.03 73.99
2013-06-30 -16.86 40.96 57.93
2013-03-31 -0.91 41.10 70.38
  • XOMA's level of debt (73.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (1215.4% vs 73.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • XOMA has sufficient cash runway for 2.9 years based on current free cash flow.
  • XOMA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -29.8% each year.
X
Financial health checks
We assess XOMA's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. XOMA has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is XOMA's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from XOMA dividends.
If you bought $2,000 of XOMA shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate XOMA's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate XOMA's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:XOMA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:XOMA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as XOMA has not reported any payouts.
  • Unable to verify if XOMA's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of XOMA's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as XOMA has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess XOMA's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can XOMA afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. XOMA has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of XOMA's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jim Neal
COMPENSATION $1,323,455
AGE 63
TENURE AS CEO 3.3 years
CEO Bio

Mr. James R. Neal, also known as Jim, serves as Director at Leading BioSciences Inc since October 30, 2018. He has been the Chief Executive Officer at XOMA Corporation since December 21, 2016 and served as its Chief Operating Officer and Senior Vice President from November 1, 2015 to December 21, 2016 and served as its Vice President of Business Development from November 2009 to November 1, 2015. Mr. Neal has years of experience forming and maximizing valuable business and technology collaborations globally and in taking novel products and technologies to market. He has life science industry leadership experience. His expertise spans such areas as development and commercialization of novel technologies and products, as well as formation and oversight of successful global business and technology collaborations. Mr. Neal served as Acting Chief Executive Officer of Entelos, Inc, a leader in bio-simulation technologies, at which he was responsible for partnerships with global pharmaceutical companies such as Eli Lilly and GlaxoSmithKline. Mr. Neal served as Chief Executive Officer and President of Entelos, Inc. He served as Chief Business Officer of Entelos, Inc. He served as Chief Executive Officer of Iconix BioSciences, Inc. since June 2002. He joined Iconix Pharmaceuticals, Inc., in June 2002. He served as Executive Vice President of Sales, Marketing and Business Development and a Member of the Executive Team at Incyte Corporation (Incyte Genomics) from 1999 to 2002. He was responsible for Incyte's global commercial activities with clients and collaborators. He joined Incyte as an Executive Officer in July 1999. Prior to Incyte, he served as General Manager of the Solaris Group, a division of Monsanto Company. Mr. Neal served various positions of increasing responsibility with Monsanto from 1982 to 1999. He has been a Director of XOMA Corporation since December 21, 2016. He served as a Director of Iconix BioSciences, Inc. Mr. Neal has his B. Sc. degree in Biology and his M. Sc. in Genetics and Plant Breeding from the University of Manitoba, Canada. He completed an Executive MBA at Washington University in 1992.

CEO Compensation
  • Jim's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Jim's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the XOMA management team in years:

3.3
Average Tenure
45
Average Age
  • The tenure for the XOMA management team is about average.
Management Team

Jim Neal

TITLE
CEO & Director
COMPENSATION
$1M
AGE
63
TENURE
3.3 yrs

Tom Burns

TITLE
Senior VP of Finance & CFO
COMPENSATION
$1M
AGE
45
TENURE
4.9 yrs

Danny Hart

TITLE
VP & General Counsel
AGE
43
TENURE
2.2 yrs
Board of Directors Tenure

Average tenure and age of the XOMA board of directors in years:

5.3
Average Tenure
63
Average Age
  • The tenure for the XOMA board of directors is about average.
Board of Directors

Denny Van Ness

TITLE
Chairman of the Board & Lead Independent Director
COMPENSATION
$201K
AGE
76
TENURE
8.6 yrs

Jim Neal

TITLE
CEO & Director
COMPENSATION
$1M
AGE
63
TENURE
3.3 yrs

Jack Wyszomierski

TITLE
Independent Director
COMPENSATION
$167K
AGE
63
TENURE
9.6 yrs

Joe Limber

TITLE
Independent Director
COMPENSATION
$160K
AGE
66
TENURE
7.3 yrs

Barbara Kosacz

TITLE
Independent Director
AGE
60
TENURE
1.2 yrs

Matthew Perry

TITLE
Independent Director
COMPENSATION
$146K
AGE
46
TENURE
3.1 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by XOMA individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
24. Mar 20 Buy James Neal Individual 23. Mar 20 23. Mar 20 1,000 $14.50 $14,500
23. Mar 20 Buy James Neal Individual 20. Mar 20 20. Mar 20 1,000 $16.41 $16,410
20. Mar 20 Buy BVF Partners LP Company 18. Mar 20 18. Mar 20 4,439 $14.52 $64,475
17. Mar 20 Buy BVF Partners LP Company 13. Mar 20 17. Mar 20 118,277 $18.34 $2,121,654
20. Dec 19 Buy BVF Partners LP Company 19. Dec 19 19. Dec 19 373,195 $22.00 $8,210,290
15. May 19 Buy BVF Partners LP Company 10. May 19 14. May 19 27,913 $14.74 $408,228
14. May 19 Sell W. Van Ness Individual 10. May 19 10. May 19 -130 $14.71 $-1,912
X
Management checks
We assess XOMA's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. XOMA has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

How Much Of XOMA Corporation (NASDAQ:XOMA) Do Institutions Own?

XOMA is a smaller company with a market capitalization of US$157m, so it may still be flying under the radar of many institutional investors. … Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. … Public Company Ownership It appears to us that public companies own 6.2% of XOMA.

Simply Wall St -

Is XOMA (NASDAQ:XOMA) Weighed On By Its Debt Load?

and every practical investor I know worries about.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. … While it does have liabilities worth noting, XOMA also has more cash than debt, so we're pretty confident it can manage its debt safely. … If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

Simply Wall St -

If You Had Bought XOMA (NASDAQ:XOMA) Stock Five Years Ago, You'd Be Sitting On A 76% Loss, Today

It is doubtless a positive to see that the XOMA Corporation (NASDAQ:XOMA) share price has gained some 63% in the last three months. … See our latest analysis for XOMA XOMA isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … If a business loses money, you want it to grow, so no surprises that the share price has dropped 25% each year in that time.

Simply Wall St -

Are Insiders Buying XOMA Corporation (NASDAQ:XOMA) Stock?

View our latest analysis for XOMA XOMA Insider Transactions Over The Last Year In the last twelve months, the biggest single purchase by an insider was when CEO & Director James Neal bought US$53k worth of shares at a price of US$13.26 per share. … Insider Ownership For a common shareholder, it is worth checking how many shares are held by company insiders. … Our data isn't picking up on much insider ownership at XOMA, though insiders do hold about US$891k worth of shares.

Simply Wall St -

Does Market Volatility Impact XOMA Corporation's (NASDAQ:XOMA) Share Price?

Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … See our latest analysis for XOMA What we can learn from XOMA's beta value Given that it has a beta of 1.58, we can surmise that the XOMA share price has been fairly sensitive to market volatility (over the last 5 years). … What this means for you: Since XOMA tends to moves up when the market is going up, and down when it's going down, potential investors may wish to reflect on the overall market, when considering the stock.

Simply Wall St -

Introducing XOMA (NASDAQ:XOMA), The Stock That Tanked 85%

Imagine if you held XOMA Corporation (NASDAQ:XOMA) for half a decade as the share price tanked 85%. … Because XOMA is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … In the last half decade, XOMA saw its revenue increase by 0.6% per year.

Simply Wall St -

Have Insiders Been Buying XOMA Corporation (NASDAQ:XOMA) Shares This Year?

We often see insiders buying up shares in companies that perform well over the long term. … So before you buy or sell XOMA Corporation (NASDAQ:XOMA), you may well want to know whether insiders have been buying or selling. … XOMA Insider Transactions Over The Last Year.

Simply Wall St -

What Kind Of Shareholder Owns Most XOMA Corporation (NASDAQ:XOMA) Stock?

Generally speaking, as a company grows, institutions will increase their ownership. … XOMA is a smaller company with a market capitalization of US$110m, so it may still be flying under the radar of many institutional investors. … Let's take a closer look to see what the different types of shareholder can tell us about XOMA

Simply Wall St -

Have Insiders Been Buying XOMA Corporation (NASDAQ:XOMA) Shares This Year?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … So we'll take a look at whether insiders have been buying or selling shares in XOMA Corporation (NASDAQ:XOMA). … It is perfectly legal for company insiders, including board members, to buy and sell stock in a company.

Simply Wall St -

What Does XOMA Corporation's (NASDAQ:XOMA) Ownership Structure Look Like?

In this analysis, my focus will be on developing a perspective on XOMA Corporation’s (NASDAQ:XOMA) latest ownership structure, a less discussed, but important factor. … Ownership structure of a company has been found to affect share performance over time. … View our latest analysis for XOMA

Simply Wall St -

Company Info

Description

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Details
Name: XOMA Corporation
XOMA
Exchange: NasdaqGM
Founded: 1981
$185,476,119
9,761,901
Website: http://www.xoma.com
Address: XOMA Corporation
2200 Powell Street,
Suite 310,
Emeryville,
California, 94608,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM XOMA Common Stock Nasdaq Global Market US USD 06. Jun 1986
DB X0M1 Common Stock Deutsche Boerse AG DE EUR 06. Jun 1986
LSE 0M26 Common Stock London Stock Exchange GB USD 06. Jun 1986
BRSE X0M1 Common Stock Berne Stock Exchange CH CHF 06. Jun 1986
Number of employees
Current staff
Staff numbers
10
XOMA employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 01:04
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/23
Last earnings filing: 2020/03/10
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.